ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS) has come to an agreement with Bachem, Inc. The agreement makes Bachem the key manufacturer of Homspera drug substance. Homspera is a peptide analog is currently being developed by ImmuneRegen for treatment of cancer, infectious diseases, pulmonary diseases and wound healing.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Bachem will be producing Homspera under the agreement. To begin Bachem will need to produce enough Homspera to support formulation, pre clinical studies and to perform Phase 1 studies in humans. The drug has to be produced under Good Manufacturing Practices (cGMP) in order to be used in humans.
About Bachem, Inc.
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
